Kornimate/medical-research-clean huggingface dataset:
the cricoid pressure in pediatric patients

Conditions: Aspiration Pneumonia; Cricoid Cartilage; Pediatric

Summary: because the cricoid force in children has not been quantified, clinicians wrongly used the 'adult' force. it has been found that the use of the adult force can result in compression and distortion of the child's airway and can lead to airway obstruction and difficult intubation. based on known measurements of the cricoid surface area in children, the theoretical forces necessary to occlude the esophageal entrance have been calculated . these forces were found to be much less than the recommended adult force and much less than the forces that distort the airway as reported previously. based on these theoretical calculations, the current study was performed to determine the effective cricoid force for pediatric groups (group 1 and group 2).

120 children asa i or ii undergoing different surgeries scheduled to undergo procedures requiring general anesthesia and endotracheal intubation were enrolled in this protocol group1 (40 pts, age 3-5 ysr) group 2 (40 pts,6-8 yrs) and group 3 ( 40 pts, 9-13 yrs) .following applying of asa standard monitoring and placement of peripheral iv cannula maximal preoxygenation was achieved (end-tidal oxygen \> 90%), and anesthesia was induced with propofol 2 mg/kg, fentanyl 1-1.5 µg/kg and sevoflurane in oxygen/air mixture. cisatracurium or rocuronuim was given to maintain muscle relaxation. gentle mask ventilation was begun following an oropharyngeal airway placement. cp was applied by the same anesthesiologist in all patients with his back toward the video monitor. the cricoid cartilage was first identified and then held between the thumb and middle finger and the pressure was applied by the index finger with a force to facilitate the manual ventilation. after loss of consciousness, the force was increased to the predertmined force. the applied cricoid force in successive patients was determined by the response of the previous patient within the same group, using biased coins up-and-down method in each group. the adjustment force interval was 1 n. successful insertion of the gt with the adjusted force, was considered ineffective cp and the force was increased 1 n for next patient. conversely, an unsuccessful gt insertion with the adjusted cricoid force was considered effective cp, and the force was decreased 1 n for the next patient. tracheal intubation was performed with the appropriate size endotracheal tube while using the same cricoid force, initially tested, and the surgical procedure was begun.

Eligibility criteria:
inclusion criteria: age : 3-14 years asa 1,2 easy identification cricoid cartilage no contre indication of cp exclusion criteria: * asa 3, 4 * difficult intubation * obese patients * contre indication of cp
evaluation of the efficacy and safety of two ibuprofen combination products for the treatment of the common cold and flu in latin america

Conditions: Common Cold

Summary: this is a multicenter, prospective, randomized, double-blind, triple-dummy, parallel group, comparative, study designed to evaluate the efficacy of ibuprofen (ibu) 200 mg/ phenylephrine (pe) 10 mg and ibu 200 mg/ pe 10 mg/ chlorpheniramine (chlor) 4 mg on the relief of symptoms of the common cold and flu. the reference product that the active treatments will be compared to is paracetamol (para) 500 mg.


Eligibility criteria:
inclusion criteria: male and female subjects who are 18 years old or older at the time of screening. subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. subjects must present with a score of 5 of higher for at least 2 of the following 6 symptoms: runny nose, plugged nose, sneezing, sore throat, scratchy throat, or head congestion on the wurss-21 assessment, within 36 hours of onset of symptoms. exclusion criteria: anyone with a history of chronic allergic rhinitis or asthma at the time of the screening visit, or with history of chronic recurrent airway disease, infections, or frequent complications of colds (otitis media, sinusitis, or bronchitis) subjects taking any prescription or non-prescription drug, within the last 7 days prior to the screening, with which the administration of ibu, pe, chlor, or apap is contraindicated, may increase the risk associated with study participation, or may interfere with the interpretation of study results, in the judgment of the investigator. subjects currently taking a monoamine oxidase (mao) inhibitor, or has taken an mao inhibitor within 2 months of screening. subjects currently taking a serotonin-selective reuptake inhibitor (ssri), tricyclic antidepressant (tca), barbiturate, or any other neuroleptic, or has taken an ssri, tca, barbiturate, or any other neuroleptic within 14 days of screening. subjects with a hypersensitivity to ibu, pe, or chlor or apap.

Keywords: common cold efficacy symptoms wisconsin upper respiratory symptom survey - 21 ibuprofen phenylephrine pseudoephedrine
maternal outcomes following manual lysis of the placenta.

Conditions: Third Stage of Delivery

Summary: comparison of maternal outcomes following manual lysis of placenta 15 vs 30 minutes after delivery. a primary outcome of the drop in hemoglobin will be compared between the two groups. secondary outcomes include maternal satisfaction, time to first breastfeeding, length of hospital stay, infection rate etc.

women undergoing spontaneous term vaginal delivery with epidural analgesia will be randomly assigned into one of two groups: 1. manual lysis of placenta 15 minutes after delivery. 2. waiting 30 minutes and then manual lysis of placenta. both groups will be managed actively during the 3rd stage of delivery, including oxytocin administration and controlled cord traction. women who develop active bleeding will be promptly treated with manual lysis and excluded from the study. manual lysis will be performed under epidural analgesia, and prophylactic antibiotics will be administered. primary outcome of comparison between the two groups: hemoglobin drop after delivery. secondary outcomes include: maternal satisfaction, time to first breastfeeding, length of hospital stay, infection rate etc.

Eligibility criteria:
inclusion criteria: * term spontaneous vaginal delivery. * singleton pregnancy. * epidural analgesia during delivery. * age between 18 and 45 years. exclusion criteria: * active bleeding after delivery that warrants prompt removal of placenta regardless of time from delivery. * vacuum extraction. * intrapartum infection. * intrapartum fever above 38 degrees celsius. * wide 3rd and 4th degree perineal tears that mandate suturing under general anaesthesia. * thalassemia carriers.

Keywords: manual lysis, postpartum hemorrhage, third stage of delivery.
long non coding rna hotair and midkine as biomarkers in thyroid cancer

Conditions: Thyroid Cancer

Summary: thyroid cancer is the most prevalent endocrine malignancy.papillary thyroid carcinomas and follicular thyroid carcinomas account for 95% of all thyroid cancer cases. they are clinically classified as well-differentiated thyroid carcinomas due to their biological behavior resembling normal follicular cells and good responsiveness to surgery and radioiodine therapy . however, they are usually curable when discovered at early stages, but survival rates may be reduced from 100% in stages i and ii to 50% at stage iv so,early detection is the key for successful treatment and reduction of mortality. pathological analysis by fine-needle aspiration biopsies has some limitations including difficulty in sampling small tumors, inconclusive diagnosis in up to 35% of patients and bleeding. thus, biomarkers for diagnosis are needed.

thyroid cancer is the most prevalent endocrine malignancy.papillary thyroid carcinomas and follicular thyroid carcinomas account for 95% of all thyroid cancer cases. they are clinically classified as well-differentiated thyroid carcinomas due to their biological behavior resembling normal follicular cells and good responsiveness to surgery and radioiodine therapy . however, they are usually curable when discovered at early stages, but survival rates may be reduced from 100% in stages i and ii to 50% at stage iv so,early detection is the key for successful treatment and reduction of mortality. pathological analysis by fine-needle aspiration biopsies has some limitations including difficulty in sampling small tumors, inconclusive diagnosis in up to 35% of patients and bleeding. thus, biomarkers for diagnosis are needed. the concept of liquid biopsy was proposed in contrast to the traditional tissue biopsy which is particularly important for solid tumor diagnosis. it refers to the process of detecting genetic materials, using non-invasive method from blood or other body fluids.long noncoding rnas (lncrnas) have recently been demonstrated to participate in cancer progression.hotair is the type of non coding rna that will be investigated for its ability to differentiate benign from malignant thyroid nodule midkine a basic heparin-binding growth factor of low molecular weight, capable of exerting activities such as cell proliferation, cell migration, angiogenesis and fibrinolysis. midkine expression is closely related with progression of tumor stage. if tumor tissues increase secretion of midkine, it becomes evident in serum.the expression of midkine gene in human tumor cells may reflect tumor formation and give clues to the biological behavior of neoplasms. hence, the expression of midkine may serve as a tumor marker for diagnosis and follow-up.

Eligibility criteria:
inclusion criteria: * patient with thyroid mass exclusion criteria: * no other known organ malignancy no previous chemotherapy
aiocc italian registry on head and neck carcinomas

Conditions: Head and Neck Carcinoma

Summary: multicentre, retrospective and prospective observational study aimed to set-up a clinical italian registry in order to collect information on carcinoma of the head and neck.

the registry plans to collect data on all patients treated or followed for head and neck cancer by the hcp of selected investigational sites in italy. data will be entered manually by hcp staff of each investigational site in the study e-crf in order to populate the air study database. authorized hcps will be provided with personal userid and password for the access to study ecrf. for data analysis an open-source system called vantage6 will be used. it is a privacy preserving federated learning infrastructure for the secure exchange and analysis of incorporating data located at different sources. queries will be issued to interrogate the database in order to have descriptive statistics and relevant information to plan the statistical analyses envisioned by the study protocol. the registry data will support observational studies based on the second hand use of available data. data collected for the air study could be used also for global collaborative studies performed in europe and outside the europe.

Eligibility criteria:
inclusion criteria: 1. adult patients (age ≥ 18 years old) diagnosed with carcinoma of the head and neck. the diagnosis should be done or verified by the expert site entering the information about the patient in the registry. patients diagnosed with sarcomas and lymphomas are excluded. 2. patients entering the hcp at any clinical phase of the disease (diagnosis, treatment of primary cancer, treatment of recurrence, treatment of m+ etc.). the hcp will collect information on the entire disease regardless of when it started to manage the patient. the hcp can choose, based on its resources, for how many patients will be able to collect the data. 3. new patients managed by the hcp from 2021 onwards + patients managed by the hcp, in active follow-up at the hospital exclusion criteria: 1. patients whose medical records are unavailable for review
intravaginal prasterone (dhea) against vulvovaginal atrophy associated with menopause

Conditions: Vaginal Atrophy

Summary: the purpose of this study is to confirm the efficacy of intravaginal prasterone (dhea) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal dhea in order to meet the ich e1 guideline requirements.


Eligibility criteria:
inclusion criteria: main criteria: * postmenopausal women (hysterectomized or not) * women between 40 and 80 years of age * women having ≤5% of superficial cells on vaginal smear at baseline * women having a vaginal ph above 5 at baseline * women who have self-identified moderate or severe symptom(s) of vaginal atrophy * willing to participate in the study and sign an informed consent exclusion criteria: main criteria: * previous enrollment in endoceutics studies performed with intravaginal dhea * previous diagnosis of cancer, except skin cancer (non melanoma) * clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication * the administration of any investigational drug within 30 days of screening visit * clinically significant abnormal serum biochemistry, urinalysis or hematology

Keywords: vulvovaginal atrophy (vva) vaginal atrophy atrophic vaginitis prasterone dhea intrarosa
solifenacin succinate 5mg or 10mg once daily in the treatment of urgency symptoms

Conditions: Urinary Bladder, Overactive

Summary: prospective, double-blind, double-randomised, 2-arm parallel group study. optimal dose increase. primary efficacy assessment of oab symptoms by patient diaries.


Eligibility criteria:
inclusion criteria: * patient is willing and able to complete the micturition diary correctly. * symptoms of overactive bladder (including urinary frequency, urgency with/without urge incontinence) for \>= 3 months * at least 3 episodes of urgency with or without incontinence in last 3 days * at least three episodes of urgency with or without incontinence (ppius grade 3 or 4) during the 3-day micturition diary period * patient must experience frequency of micturition on average \>= 8 times per 24-hour period during the 3-day micturition diary period exclusion criteria: * pregnant women or women who intend to become pregnant during the study or women of childbearing potential who are sexually active and practising an unreliable method of birth control or will be lactating during the study. reliable contraceptive methods are intra-uterine devices, contraceptive pills of combination type, hormonal implants and injectable or patch contraceptives * clinically significant outflow obstruction (at the discretion of the investigator) * significant post void residual volume (pvr\>200ml) * significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator * patient with indwelling catheters or practising intermittent self-catheterisation * evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs * hypersensitivity to solifenacin or to any of the excipients, uncontrolled narrow angle glaucoma, myasthenia gravis, urinary or gastric retention, severe renal impairment (gfr ≥30 ml/min), moderate or severe hepatic impairment, chronic intestinal disease, megacolon, requirement for dialysis, concomitant use of a strong cyp3a4 inhibitor, e.g. ketoconazole * non drug oab treatment such as bladder-training, biofeedback and pelvic floor exercises are permissible if established at least 4 weeks prior to study start and intended to be continued throughout the study; electrostimulation therapy is not permissible at any time * use of drugs intended to treat urinary incontinence * diabetic neuropathy * any clinically significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial * participation in any clinical trial within 30 days prior to randomisation * employees of the yamanouchi group, third parties associated with the study, or the study site * patient who did not complete the micturition diary according to the instructions

Keywords: overactive bladder
determine the percentage of depressed outpatients who do not effectively metabolize extended-release venlafaxine hcl

Conditions: Depression

Summary: this is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine hcl (u.s. marketed brand effexor xr®) who are poor metabolizers (based on the levels of the drug in the blood) at 2d6 (a system in the liver that breaks down some medications and other chemicals).


Eligibility criteria:
inclusion criteria: * men and women subjects aged 18 years or older. * current outpatient treatment with extended-release venlafaxine hcl (u.s. marketed brand effexor xr®), within the us food and drug administration (fda)-approved dosage range for depression (37.5 mg/day to 225 mg/day), for 8 weeks or less. * ability to have a blood draw within 4 to 12 hours of the most recent dose of effexor xr®. exclusion criteria: * determination by the investigator that a blood draw is contraindicated. * participation in an investigational study within the past 30 days where the study medication is not known. * previous treatment with effexor xr® or extended-release venlafaxine hcl (generic) in the 6 months prior to current treatment regimen. * treatment with dvs sr within the last 30 days.
effectiveness of nurse tele-consultation on the quality of elective colonoscopy, procedure-related anxiety, and financial toxicity

Conditions: Patient Satisfaction and Efficacy of Bowel-preparation; Colon Cancer Prevention

Summary: this is a multicenter, non-pharmacological, experimental, prospective, randomized study, with two arms (1:1) in a single-blind design. the study aims to evaluate the effectiveness of a tele-consultation procedure in patients undergoing elective colonoscopy in terms of quality of the exam, anxiety procedure-related and financial toxicity.

the aim of this study is to evaluate the effectiveness, in daily clinical practice, of a tele-consultation procedure (defined as a telephone consultation with the patient conducted by nursing staff with an appropriate level of experience in digestive endoscopy) with the goal of: 1. improving adherence to methods and timing for the correct intake of the intestinal preparation by patients undergoing elective colonoscopy; 2. assessing whether the tele-consultation can reduce anxiety and procedure-related stress, promoting a better emotional state in patients undergoing colonoscopy.

Eligibility criteria:
inclusion criteria: subjects eligible for outpatient pancolonoscopy: * for diagnostic purposes; * for screening purposes; * for post-polypectomy follow-up; * of both genders; * of all ethnicities; exclusion criteria: * patients under 18 years of age or over 80 years of age; * patients on waiting lists with short priority: the procedure to be provided within a short time (no more than 10 days); * patients included in gom pathways who undergo colonoscopy within 10 days; * pregnancy; * presence of known contraindications to bowel preparation; * presence of known contraindications to performing pancolonoscopy; * patients who have undergone colonic resection and/or have a colostomy/ileostomy; * patients with cognitive impairments; * patients declared legally incompetent or unable to understand and make decisions; * patients unable to provide informed consent.

Keywords: colonoscopy tele-consultation procedure colon cancer financial toxicity anxiety procedure-related
a su011248 expanded access protocol for systemic therapy of patients with metastatic renal cell carcinoma who are ineligible for participation in other su011248 protocols but may derive benefit from treatment with su011248

Conditions: Metastatic Renal Cell Carcinoma

Summary: a su011248 expanded access protocol for systemic therapy of patients with metastatic renal cell carcinoma who are ineligible for participation in other su011248 protocols but may derive benefit from treatment with su011248


Eligibility criteria:
inclusion criteria: * patients with metastatic renal cell carcinoma who are ineligible for participation in other su011248 protocols but may derive benefit from treatment with su011248
amotosalen-ultraviolet a pathogen-inactivated convalescent plasma in addition to best supportive care and antiviral therapy on clinical deterioration in adults presenting with moderate to severe covid-19

Conditions: Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)

Summary: this project investigates individual treatments using convalescent severe acute respiratory syndrome coronavirus 2 (sars-cov-2) plasma in sars-cov-2 infected patients at risk for disease progression. in addition to standard of care, sars-cov-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.


Eligibility criteria:
inclusion criteria for donors: * male patients who have been tested positive for sars-cov2 at university hospital basel, switzerland or in the near surroundings more than 10 days before enrolment * 18-60 years of age * asymptomatic (thus successfully overcome covid-19) \>14 days back * two consecutive naso-pharyngeal swabs tested negative for quantitative pcr-test for sars-cov-2 prior to plasma donation to demonstrate infection resolution, or more than 28 days asymptomatic after sars-cov2 infection * body weight of at least 50 kg * donor eligibility criteria according to the swiss red cross blood transfusion service as for regular blood donation exclusion criteria for donors: * female donors are excluded from plasma donation * treatment with actemra® (tocilizumab) in the course of covid-19 * current hospitalization * current or previous relevant medical conditions that pose a risk for the donor inclusion criteria for covid-19 infected patients: * sars-cov-2 infection confirmed by pcr in respiratory secretions (naso- pharyngeal swab, broncho-alveolar lavage, sputum) * hospitalized * pulmonary infiltrates compatible with covid-19 on ct-scan * availability of blood group compatible convalescent plasma * signed informed consent

Keywords: convalescent plasma severe acute respiratory syndrome coronavirus 2 (sars-cov-2)